C Parker - The Lancet, 2009 - Elsevier The complement system plays a central part in both innate and acquired immunity, but the contribution
of complement activation to pathobiology is largely ancillary. An exception to the non-dominant
role of complement in disease is the haemolytic anaemia of paroxysmal nocturnal ... Cited by 6 - Related articles - All 18 versions
- ►hematologylibrary.org RA Brodsky - Hematology, 2008 - asheducationbook. … Paroxysmal nocturnal hemoglobinuria is a clonal hematopoietic stem cell disease that manifests
with intravascular hemolysis, bone marrow failure, thrombosis, and smooth muscle
dystonias. The disease can arise de novo or in the setting of acquired aplastic anemia. All ... Cited by 3 - Related articles - All 2 versions
- ►hematologylibrary.org RA Brodsky - Blood, 2009 - bloodjournal.hematologylibrary.org Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with
hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of
the disease result from complement-mediated intravascular hemolysis. Allogeneic bone ... Cited by 3 - Related articles
R Hu, GL Mukhina, SH Lee, RJ Jones, PT Englund, … - Experimental …, 2009 - Elsevier Burkitt lymphoma cell lines harbor large populations of FLAER neg cells, which are resistant
to proaerolysin. In all three cell lines, silencing of a gene involved in an early step in GPI-anchor
biosynthesis was responsible for the lack of GPI-anchored proteins on the cell surface. ... Related articles - All 9 versions
RA Brodsky - Expert Rev. Hematol., 2009 - expert-reviews.com Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease that
can present with bone marrow failure, hemolytic anemia and thrombosis [1,2]. The disease originates
from a multipotent hematopoietic stem cell that acquires a PIG-A mutation [3,4]. ... Related articles - All 2 versions
CJ Parker, RA Brodsky, JE Levine - Biology of Blood and Marrow …, 2008 - Elsevier For many malignant and nonmalignant hematologic conditions, the only effective therapy is allogeneic
hematopoietic cell transplantation (HCT). In these settings, the consulting transplant physician
often has the luxury of focusing on the reasons why HCT is necessary and the risks of ... Related articles - All 16 versions
DH Yang, DM Chang, JH Lai, FH Lin, CH Chen - Rheumatology, 2009 - Br Soc Rheumatology Objective. SLE is an autoimmune disorder characterized by abnormal complement
activation. Numerous new biomarkers have recently been used to diagnose or monitor disease
activity in patients with SLE. We checked the levels of erythrocyte-bound C4d (E-C4d), an ... Related articles - All 3 versions
HD Pettigrew, SS Teuber, ME … - Annals of the New York …, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Related articles - All 3 versions
[CITATION] Last literature review version 17.1: Thu Jan 01 00: 00: 00 GMT 2009| This topic last …
AL Singer, JE Locke, ZA Stewart, BE Lonze, JP … - Hepatology - interscience.wiley.com Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by
somatic mutations in the phosphatidylinositol glycan-complementation class A gene and the
resulting absence of a key complement regulatory protein, CD59. Affected red blood cells ... Related articles - All 2 versions
